USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
19 - 22 Oct 2025 | Las Vegas

Buy Now, Weigh Less Later

Keep exploring for FREE!

Create a free account or log in to unlock content, event past recordings and more!

Speakers:

Anand Iyer Chief AI OfficerWelldoc
Anand Iyer
Chief AI OfficerWelldoc
Bethanie Stein President, Humana’s Pharmacy BusinessCenterWell
Bethanie Stein
President, Humana’s Pharmacy BusinessCenterWell
Demetri Karagas CEOThirty Madison
Demetri Karagas
CEOThirty Madison
Laura Jensen CCO and President of Pharma SolutionsGoodRx
Laura Jensen
CCO and President of Pharma SolutionsGoodRx
Madison Muller Health reporterBloomberg
Madison Muller
Health reporterBloomberg

About this Session:

The GLP-1 market is forcing everyone from insurers to patients to get creative about who pays for those thousand-dollar-a-month medications. While Medicare has halted coverage for obesity drugs, and multiple insurers cite GLP-1 costs as contributing factors to their 2024 financial losses, the industry is scrambling to find payment models that don't break the bank or leave patients empty-handed. Major pharmaceutical companies have struck deals with direct-to-consumer providers to sell GLP-1 drugs at half the traditional price, while insurers are taking dramatically different approaches to manage costs. Some are playing favorites by making certain GLP-1s their preferred option and dropping competitors, while others are betting on comprehensive programs that now cover millions of enrollees.The desperation for affordable access has spawned entirely new financial models from buy-now-pay-later partnerships to insurance crowdfunding alternatives. Around one-third of major PBM clients simply choose not to cover GLP-1s for weight loss, highlighting the tension between the drugs' proven benefits and their unsustainable costs. The industry is reinventing payment structures and exploring whether these financial models can scale. Maintaining a healthy weight shouldn’t cost you your financial health too.